找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Novel Synthetic Drugs in Migraine; Paolo Martelletti,Lars Edvinsson Book 2022 The Editor(s) (if applicable) and The Author(s), under exclu

[復(fù)制鏈接]
查看: 51112|回復(fù): 43
樓主
發(fā)表于 2025-3-21 17:37:18 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Novel Synthetic Drugs in Migraine
編輯Paolo Martelletti,Lars Edvinsson
視頻videohttp://file.papertrans.cn/669/668457/668457.mp4
概述First book on the novel synthetic treatment of migraine.Compares gepants with triptans or CGRP monoclonal antibodies.Compares ditans with triptans
叢書名稱Headache
圖書封面Titlebook: Novel Synthetic Drugs in Migraine;  Paolo Martelletti,Lars Edvinsson Book 2022 The Editor(s) (if applicable) and The Author(s), under exclu
描述.Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development..
出版日期Book 2022
關(guān)鍵詞acute treatment; preventive treatment; gepants; ditans; Pharmacological Targets
版次1
doihttps://doi.org/10.1007/978-3-030-95334-8
isbn_softcover978-3-030-95336-2
isbn_ebook978-3-030-95334-8Series ISSN 2197-652X Series E-ISSN 2197-6538
issn_series 2197-652X
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Novel Synthetic Drugs in Migraine影響因子(影響力)




書目名稱Novel Synthetic Drugs in Migraine影響因子(影響力)學(xué)科排名




書目名稱Novel Synthetic Drugs in Migraine網(wǎng)絡(luò)公開度




書目名稱Novel Synthetic Drugs in Migraine網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Novel Synthetic Drugs in Migraine被引頻次




書目名稱Novel Synthetic Drugs in Migraine被引頻次學(xué)科排名




書目名稱Novel Synthetic Drugs in Migraine年度引用




書目名稱Novel Synthetic Drugs in Migraine年度引用學(xué)科排名




書目名稱Novel Synthetic Drugs in Migraine讀者反饋




書目名稱Novel Synthetic Drugs in Migraine讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-22 00:14:48 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:53:17 | 只看該作者
地板
發(fā)表于 2025-3-22 05:17:05 | 只看該作者
5#
發(fā)表于 2025-3-22 10:22:39 | 只看該作者
6#
發(fā)表于 2025-3-22 14:32:02 | 只看該作者
Zavegepant,inical data are available regarding its therapeutic efficacy and safety profile. Data on metabolism, pharmacogenomics, and pharmacokinetics profile are limited, therefore new studies are needed to define its efficacy, safety, tolerability, and pharmacological interaction.
7#
發(fā)表于 2025-3-22 20:13:32 | 只看該作者
Molecular Mechanisms of 5-HT1F Receptor Agonists,igraine. Updated evidence suggests that ditans exert their antimigraine effects by modulating the trigeminovascular system, while devoid of cardiovascular safety drawbacks shared by previous antimigraine drugs targeting 5-HT receptors, namely ergot-derivatives and triptans.
8#
發(fā)表于 2025-3-22 22:39:34 | 只看該作者
Update on Old and Current Targets for Antimigraine Therapies,hese are effective with few side effects. In this chapter, we discuss mechanisms involved in the use of and treatment with the different medications and use their effectiveness to understand a bit more of the underlying biology of migraine.
9#
發(fā)表于 2025-3-23 04:36:12 | 只看該作者
Book 2022ith ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature
10#
發(fā)表于 2025-3-23 08:07:23 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 12:31
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
共和县| 西昌市| 绿春县| 冷水江市| 南昌县| 措美县| 盈江县| 叶城县| 轮台县| 桐柏县| 墨玉县| 特克斯县| 五指山市| 册亨县| 丹阳市| 綦江县| 白城市| 莲花县| 雷州市| 静安区| 江川县| 平定县| 大竹县| 青田县| 贺州市| 昌江| 铁力市| 郸城县| 拉萨市| 塔河县| 河池市| 益阳市| 共和县| 神木县| 法库县| 苍梧县| 永年县| 天气| 宁武县| 寿宁县| 宜都市|